Summary
This 8-K filing from Amgen Inc. (AMGN), dated July 30, 2013, primarily announces the company's unaudited financial results for the second quarter and first half of 2013. The report details adjustments made to GAAP financial measures to present non-GAAP financial results, which the company believes offer investors a clearer view of operational performance by excluding certain non-cash items, acquisition-related expenses, cost-saving initiatives, legal expenses, and other one-time or non-recurring charges. Key to investors is Amgen's focus on providing supplementary non-GAAP metrics, including adjusted earnings per share and Free Cash Flow (FCF). These adjustments aim to normalize financial reporting, allowing for better comparability across periods and against peers by isolating core operational performance. The company explicitly states its belief that these non-GAAP measures aid in analysis and are used internally for budgeting and financial planning.
Key Highlights
- 1Amgen announced its unaudited financial results for the three and six months ended June 30, 2013.
- 2The company presented non-GAAP financial measures alongside GAAP results, citing enhanced analytical value for investors.
- 3Key non-GAAP adjustments include excluding non-cash amortization of intangible assets, acquisition-related expenses, stock option expensing, cost-saving initiatives, legal expenses, and non-cash interest expense.
- 4The report highlights the presentation of Free Cash Flow (FCF) as a non-GAAP measure, defined as cash flow from operations less capital expenditures.
- 5Amgen also reported non-GAAP adjusted earnings per share including the impact of stock option expensing for comparability.
- 6The filing references a press release (Exhibit 99.1) dated July 30, 2013, which contains the detailed financial results and reconciliations.
- 7Jonathan M. Peacock, Executive Vice President and Chief Financial Officer, signed the report.